Syngene International Limited (SYNGENE.NS) NSE

Currency In INR

AD

Syngene International Limited

Address

Biocon SEZ, Biocon Park,

Bengaluru, KA 560099

India

Phone

91 80 2808 2808

Sector

Healthcare

Industry

Biotechnology

Employees

6510

First IPO Date

August 11, 2015

Key Executives

NameTitlePayYear Born
Siddharth MittalChief Executive Officer, MD & Director400,0001978
Peter James Jonathan BainsChief Executive Officer, MD & Director400,0001957
Kiran Mazumdar-ShawExecutive Chairperson7.1M1953
Surender Kumar SharmaGeneral Counsel01975
Chethan YogeshCompany Secretary & Compliance Officer0N/A
Gaurav KushwahaChief Technology Officer0N/A
Jayashree AiyarChief Scientific Officer0N/A
Maninder Kapoor PuriChief Human Resources Officer01973
Sandeep NairHead of Corporate Communications0N/A
Deepak JainChief Financial Officer0N/A
Ajay TandonHead of Strategy & Corporate Development0N/A
KrishnanHead of Investor Relations0N/A
AD

Description

Syngene International Limited, an India-based contract research and manufacturing organization (CRAMO), offers a wide array of drug discovery and development solutions to clients across India, the United States, and other international markets. The company's comprehensive service portfolio begins with discovery chemistry, encompassing medicinal and synthetic chemistry, library and peptide synthesis, biomolecule research, organic electronic materials, and specialized computational and analytical chemistry. In discovery biology, capabilities extend to recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK (Drug Metabolism and Pharmacokinetics), in vivo pharmacology, toxicology, and the development of biologicals. Syngene provides a full spectrum of toxicology services, from exploratory and in vitro studies to genetic, developmental, and reproductive toxicology, alongside acute, sub-chronic, and chronic toxicity assessments. Their development services include chemical, formulation, analytical, and clinical development, as well as commercial manufacturing. They also support crucial stages like lead generation, preclinical development, API (Active Pharmaceutical Ingredient) synthesis, and finished drug product development. For clinical trials, Syngene offers robust support, covering trial management, pharmacokinetic analysis/bioanalytical services, central laboratory operations, biometrics and clinical data management, regulatory affairs, medical monitoring, pharmacovigilance, and medical writing. Additionally, the company specializes in emerging drug modalities, such as peptides, oligonucleotide synthesis, antibody-drug conjugates (ADCs), PROTACs, and CAR T-cell therapies. Serving a diverse clientele that spans pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical industries, Syngene has established key collaborations with entities like Bristol-Myers Squibb Co., Baxter Inc., and Amgen Inc. Incorporated in 1993 and headquartered in Bengaluru, India, Syngene International Limited operates as a subsidiary of Biocon Limited.

AD